

Edgar Filing: TRANSGENOMIC INC - Form 8-K

TRANSGENOMIC INC  
Form 8-K  
April 04, 2005

=====

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):  
MARCH 31, 2005

TRANSGENOMIC, INC.  
(Exact name of registrant as specified in its charter)

Delaware  
(State of Formation)

000-30975  
(Commission File Number)

911789357  
(IRS Employer Identification Number)

12325 Emmet Street  
Omaha, NE  
(Address of principal executive offices)

68164  
(Zip Code)

(402) 452-5400  
(Registrants' telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e(c))

=====

ITEM 3.01 NOTICE OF DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR STANDARD.

## Edgar Filing: TRANSGENOMIC INC - Form 8-K

On March 31, 2005, the Registrant received notice from The NASDAQ Stock Market that for the last 30 days the bid price of Registrant's common stock has closed below the minimum \$1.00 per share requirement for continued inclusion under Marketplace Rule 4450(a)(5). In accordance with Marketplace Rule 4450(e)(2), Registrant will be provided 180 calendar days, or until September 27, 2005, to regain compliance. The Registrant has not determined an action or response to the notice as of the time of this filing.

2

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TRANSGENOMIC, INC.

By /s/ Michael Summers

-----  
Michael Summers  
Chief Financial Officer

April 4, 2005

3